Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells 5,000 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the transaction, the director now directly owns 33,611 shares in the company, valued at $1,972,629.59. This represents a 12.95 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Jeffrey William Henderson also recently made the following trade(s):

• On Monday, February 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $56.30, for a total value of $281,500.00.
• On Monday, January 6th, Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock traded down $1.19 during midday trading on Monday, hitting $57.96. 1,414,542 shares of the company’s stock were exchanged, compared to its average volume of 1,294,096. The company has a market cap of $7.14 billion, a P/E ratio of 16.90, a PEG ratio of 0.42 and a beta of 1.25. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The stock has a 50-day moving average price of $54.53 and a two-hundred day moving average price of $54.72. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. HC Wainwright upped their price target on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Piper Sandler raised their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Benchmark reiterated a “buy” rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, Wells Fargo & Company dropped their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $62.78.

Hedge Funds Weigh In On Halozyme Therapeutics

Institutional investors have recently made changes to their positions in the stock. Heck Capital Advisors LLC purchased a new position in Halozyme Therapeutics in the fourth quarter worth $29,000. CBIZ Investment Advisory Services LLC bought a new stake in Halozyme Therapeutics during the fourth quarter worth about $29,000. Smartleaf Asset Management LLC boosted its holdings in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 197 shares in the last quarter. Venturi Wealth Management LLC bought a new position in shares of Halozyme Therapeutics during the 4th quarter valued at about $69,000. Finally, Parkside Financial Bank & Trust raised its holdings in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 322 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.